Citius Oncology (CTOR) Assets Average (2022 - 2026)

Citius Oncology (CTOR) has reported Assets Average for 5 consecutive years, with $106.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average rose 16.19% year-over-year to $106.4 million in Q2 2026; TTM through Jun 2026 was $106.4 million, a 16.19% increase from a year earlier, with the FY2025 full-year figure at $92.7 million, up 18.04% from the prior year.
• Assets Average was $106.4 million for Q2 2026 at Citius Oncology, up from $105.3 million in the prior quarter.
• Over five years, Assets Average peaked at $106.4 million in Q2 2026 and troughed at $191583.5 in Q3 2022.
• A 5-year average of $71.9 million and a median of $68.9 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average surged 30587.75% in 2023 and retreated 29.42% in 2024, its largest moves.
• Over 5 years, Assets Average stood at $34.2 million in 2022, then jumped by 75.84% to $60.2 million in 2023, then jumped by 45.27% to $87.4 million in 2024, then grew by 20.63% to $105.5 million in 2025, then advanced by 0.89% to $106.4 million in 2026.
• The last three Assets Average figures came in at $106.4 million (Q2 2026), $105.3 million (Q1 2026), and $105.5 million (Q4 2025), per Business Quant data.